2-amino-3-sulfanylpropanoic acid;N,N-dimethyl-2,2-diphenylacetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-3-sulfanylpropanoic acid;N,N-dimethyl-2,2-diphenylacetamide
• 化学式: C19H24N2O3S
• 分子量: 360.5
• InChiKey: OQYNTCLQMNNLBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.23
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  84.6
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Cystine Diamide Analogs for the Prevention of Cystine Stone Formation in Cystinuria
  申请人：Rutgers, The State University of New Jersey

  公开号：US20140187546A1

  公开（公告）日：2014-07-03

  Cystine analogs that improve the solubility of L-cystine in urine for treatment of cystinuria and which have the structure: and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein each R and R′ pair are independently selected from (i) or (ii); (i) R and R′ are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alcohol, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, and substituted or unsubstituted heteroaryl, or (ii) R and R′ together form a substituted or unsubstituted heterocyclic ring structure, or a substituted or unsubstituted heteroaryl ring structure; X is hydrogen, or an alkyl; and Y is O or S.

  改善L-半胱氨酸在尿液中的溶解度以治疗囊胱氨酸尿症的半胱氨酸类似物，其结构为：以及其药用可接受的盐、溶剂化合物和前药，其中每个R和R′对均独立地从(i)或(ii)中选择；(i) R和R′均独立地从氢、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的醇、取代或未取代的芳基、取代或未取代的环烷基、取代或未取代的杂环基和取代或未取代的杂芳基中选择，或(ii) R和R′共同形成取代或未取代的杂环戒结构或取代或未取代的杂芳环结构；X为氢或烷基；Y为O或S。
• Cystine diamide analogs for the prevention of cystine stone formation in cystinuria
  申请人：Rutgers, The State University of New Jersey

  公开号：US10836737B2

  公开（公告）日：2020-11-17

  Cystine analogs that improve the solubility of L-cystine in urine for treatment of cystinuria and which have the structure: and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein each R and R′ pair are independently selected from (i) or (ii); (i) R and R′ are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alcohol, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, and substituted or unsubstituted heteroaryl, or (ii) R and R′ together form a substituted or unsubstituted heterocyclic ring structure, or a substituted or unsubstituted heteroaryl ring structure; X is hydrogen, or an alkyl; and Y is O or S.

  可改善 L-胱氨酸在尿液中的溶解度，用于治疗胱氨酸尿症的胱氨酸类似物，其结构如下： 1： 及其药学上可接受的盐、溶液剂和原药，其中 每对 R 和 R′独立选自(i)或(ii)； (i) R 和 R′独立地选自氢、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的醇基、取代或未取代的芳基、取代或未取代的环烷基、取代或未取代的杂环基和取代或未取代的杂芳基，或 (ii) R 和 R′共同形成取代或未取代的杂环环结构，或取代或未取代的杂芳基环结构； X 是氢或烷基；Y 是 O 或 S。
• CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA
  申请人：Rutgers, The State University of New Jersey

  公开号：US20160362386A1

  公开（公告）日：2016-12-15

  Cystine analogs that improve the solubility of L-cystine in urine for treatment of cystinuria and which have the structure: and pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein each R and R′ pair are independently selected from (i) or (ii); (i) R and R′ are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alcohol, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic, and substituted or unsubstituted heteroaryl, or (ii) R and R′ together form a substituted or unsubstituted heterocyclic ring structure, or a substituted or unsubstituted heteroaryl ring structure; X is hydrogen, or an alkyl; and Y is O or S.
• US9428453B2
  申请人：——

  公开号：US9428453B2

  公开（公告）日：2016-08-30